Identification
- Summary
Aminobenzoic acid is a drug used to reduce the progression of penile deviation in Peyronie's Disease in adults.
- Generic Name
- Aminobenzoic acid
- DrugBank Accession Number
- DB02362
- Background
A member of the vitamin B complex. It used to be common in sunscreening agents until found to also be a sensitizer. The potassium salt is used therapeutically in fibrotic skin disorders.
- Type
- Small Molecule
- Groups
- Approved, Experimental
- Structure
Structure for Aminobenzoic acid (DB02362)
- Weight
- Average: 137.136
Monoisotopic: 137.047678473 - Chemical Formula
- C7H7NO2
- Synonyms
- 1-Amino-4-carboxybenzene
- 4-aminobenzoic acid
- 4-Carboxyaniline
- Aminobenzoic acid
- p-Aminobenzoic acid
- p-Carboxyaniline
- p-Carboxyphenylamine
- para-Aminobenzoic acid
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Management of Peyronie's disease •••••••••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
Target Actions Organism Up-hydroxybenzoate hydroxylase substrate- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs Browse all" title="About SNP Mediated Effects/ADRs" id="snp-actions-info" class="drug-info-popup" href="javascript:void(0);">
- Not Available
Interactions
- Drug Interactions Learn More" title="About Drug Interactions" id="structured-interactions-info" class="drug-info-popup" href="javascript:void(0);">
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.Not Available
- Food Interactions
- No interactions found.
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Product Ingredients
Ingredient UNII CAS InChI Key Aminobenzoate potassium 41KZS5432U 138-84-1 MZKKJVZIFIQOPP-UHFFFAOYSA-M Aminobenzoate sodium 75UI7QUZ5J 555-06-6 XETSAYZRDCRPJY-UHFFFAOYSA-M - International/Other Brands
- Pabagel (Owen) / Pabalate (Robins) / Pabanol (Elder)
- Brand Name Prescription Products
Name Dosage Strength Route Labeller Marketing Start Marketing End Region Image Potaba Cap 0.5gm Capsule 500 mg Oral Glenwood Inc. 1985-12-31 2015-06-18 Canada 
Potaba Pwr 2gm/pck Powder 2 g / pck Oral Glenwood Inc. 1986-12-31 2012-06-29 Canada Potaba Tab 0.5gm Tablet 500 mg Oral Glenwood Inc. 1985-12-31 2014-07-31 Canada - Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image MENOPACE KAPSUL, 30 ADET Aminobenzoic acid (30 mg) + Ascorbic acid (45 mg) + Biotin (30 mcg) + Boron (2 mg) + Chromium picolinate (50 mcg) + Copper (1 mg) + Cyanocobalamin (9 mcg) + Folic acid (400 mcg) + Iodine (225 mcg) + Iron (12 mg) + Magnesium (100 mg) + Manganese (2 mg) + Niacin (20 mg) + Pantothenic acid (30 mg) + Pyridoxine (40 mg) + Riboflavin (5 mg) + Selenium (100 mcg) + Thiamine (10 mg) + Vitamin A (750 mcg) + Vitamin D (2.5 mcg) + Vitamin E (30 mg) + Zinc (15 mg) Capsule Oral NOBEL İLAÇ SAN. VE TİC. A.Ş. 1999-07-22 2020-05-28 Turkey 
Neutral C + Coenzyme Q10 Plus Vitamins & Minerals Aminobenzoic acid (15 mg / cap) + Calcium ascorbate (320 mg / cap) + Cyanocobalamin (150 mcg / cap) + Folic acid (0.5 mg / cap) + Magnesium oxide (50 mg / cap) + Potassium gluconate (3 mg / cap) + Pyridoxine hydrochloride (25 mg / cap) + Sodium selenite (40 mcg / cap) + Ubidecarenone (10 mg / cap) Capsule Oral New Vision Nutritionals Company 1998-06-07 2002-11-20 Canada Presun 15 Lotion Aminobenzoic acid (5 %) + Oxybenzone (3 %) + Padimate O (5 %) Lotion Topical Westwood Squibb, Division Of Bristol Myers Squibb Canada Inc. 1991-12-31 1997-08-11 Canada
Categories
- ATC Codes
- D02BA01 — Aminobenzoic acid
- D02BA — Protectives against UV-radiation for topical use
- D02B — PROTECTIVES AGAINST UV-RADIATION
- D02 — EMOLLIENTS AND PROTECTIVES
- D — DERMATOLOGICALS
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of organic compounds known as aminobenzoic acids. These are benzoic acids containing an amine group attached to the benzene moiety.
- Kingdom
- Organic compounds
- Super Class
- Benzenoids
- Class
- Benzene and substituted derivatives
- Sub Class
- Benzoic acids and derivatives
- Direct Parent
- Aminobenzoic acids
- Alternative Parents
- Benzoic acids / Benzoyl derivatives / Aniline and substituted anilines / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Primary amines / Organopnictogen compounds / Organooxygen compounds / Organic oxides show 1 more
- Substituents
- Amine / Amino acid / Amino acid or derivatives / Aminobenzoic acid / Aniline or substituted anilines / Aromatic homomonocyclic compound / Benzoic acid / Benzoyl / Carboxylic acid / Carboxylic acid derivative show 9 more
- Molecular Framework
- Aromatic homomonocyclic compounds
- External Descriptors
- aminobenzoic acid (CHEBI:30753)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- TL2TJE8QTX
- CAS number
- 150-13-0
- InChI Key
- ALYNCZNDIQEVRV-UHFFFAOYSA-N
- InChI
- InChI=1S/C7H7NO2/c8-6-3-1-5(2-4-6)7(9)10/h1-4H,8H2,(H,9,10)
- IUPAC Name
- 4-aminobenzoic acid
- SMILES
- NC1=CC=C(C=C1)C(O)=O
References
- Synthesis Reference
Si-Joon Lee, Hee-Young Jung, "Alpha-tocopherol 4-aminobenzoic acid ester compounds and method for preparing the same." U.S. Patent US6222051, issued January, 1986.
US6222051- General References
- Not Available
- External Links
- Human Metabolome Database
- HMDB0001392
- KEGG Drug
- D02456
- KEGG Compound
- C00568
- PubChem Compound
- 978
- PubChem Substance
- 46504695
- ChemSpider
- 953
- BindingDB
- 50145829
- 74
- ChEBI
- 30753
- ChEMBL
- CHEMBL542
- ZINC
- ZINC000000000920
- PDBe Ligand
- PAB
- Wikipedia
- Aminobenzoic_acid
- PDB Entries
- 1ius / 1iut / 1iuu / 1pbd / 2dza / 3q2a / 3tyz / 5z79 / 6day / 7pd5 … show 3 more
Clinical Trials
- Clinical Trials Learn More" title="About Clinical Trials" id="clinical-trials-info" class="drug-info-popup" href="javascript:void(0);">
Phase Status Purpose Conditions Count
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Tablet Oral Tablet, film coated Oral Capsule Oral Capsule Oral 500 mg Powder Oral 2 g / pck Tablet Oral 500 mg Powder Oral 3 g Lotion Topical Capsule, gelatin coated Oral - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
Property Value Source melting point (°C) 188.5 °C PhysProp water solubility 6110 mg/L (at 30 °C) YALKOWSKY,SH & HE,Y (2003) logP 0.83 HANSCH,C ET AL. (1995) logS -0.4 ADME Research, USCD pKa 2.38 (at 25 °C) KORTUM,G ET AL (1961) - Predicted Properties
Property Value Source Water Solubility 4.41 mg/mL ALOGPS logP 0.78 ALOGPS logP 0.8 Chemaxon logS -1.5 ALOGPS pKa (Strongest Acidic) 4.77 Chemaxon pKa (Strongest Basic) 2.69 Chemaxon Physiological Charge -1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 2 Chemaxon Polar Surface Area 63.32 Å2 Chemaxon Rotatable Bond Count 1 Chemaxon Refractivity 38.01 m3·mol-1 Chemaxon Polarizability 13.44 Å3 Chemaxon Number of Rings 1 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
Property Value Probability Human Intestinal Absorption + 0.957 Blood Brain Barrier + 0.8436 Caco-2 permeable + 0.7127 P-glycoprotein substrate Non-substrate 0.8718 P-glycoprotein inhibitor I Non-inhibitor 0.9933 P-glycoprotein inhibitor II Non-inhibitor 0.9847 Renal organic cation transporter Non-inhibitor 0.9312 CYP450 2C9 substrate Non-substrate 0.8483 CYP450 2D6 substrate Non-substrate 0.9026 CYP450 3A4 substrate Non-substrate 0.8251 CYP450 1A2 substrate Non-inhibitor 0.87 CYP450 2C9 inhibitor Non-inhibitor 0.9046 CYP450 2D6 inhibitor Non-inhibitor 0.9844 CYP450 2C19 inhibitor Non-inhibitor 0.9552 CYP450 3A4 inhibitor Non-inhibitor 0.9397 CYP450 inhibitory promiscuity Low CYP Inhibitory Promiscuity 0.9841 Ames test Non AMES toxic 0.9482 Carcinogenicity Non-carcinogens 0.5373 Biodegradation Ready biodegradable 0.637 Rat acute toxicity 1.3620 LD50, mol/kg Not applicable hERG inhibition (predictor I) Weak inhibitor 0.9841 hERG inhibition (predictor II) Non-inhibitor 0.9781
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Chromatographic Properties
Collision Cross Sections (CCS)
Adduct CCS Value (Å2) Source type Source [M-H]- 127.684712 predictedDarkChem Lite v0.1.0 [M-H]- 127.951212 predictedDarkChem Lite v0.1.0 [M-H]- 127.997312 predictedDarkChem Lite v0.1.0 [M-H]- 121.40838 predictedDeepCCS 1.0 (2019) [M-H]- 127.684712 predictedDarkChem Lite v0.1.0 [M-H]- 127.951212 predictedDarkChem Lite v0.1.0 [M-H]- 127.997312 predictedDarkChem Lite v0.1.0 [M-H]- 121.40838 predictedDeepCCS 1.0 (2019) [M+H]+ 128.830212 predictedDarkChem Lite v0.1.0 [M+H]+ 128.692512 predictedDarkChem Lite v0.1.0 [M+H]+ 128.786712 predictedDarkChem Lite v0.1.0 [M+H]+ 125.12633 predictedDeepCCS 1.0 (2019) [M+H]+ 128.830212 predictedDarkChem Lite v0.1.0 [M+H]+ 128.692512 predictedDarkChem Lite v0.1.0 [M+H]+ 128.786712 predictedDarkChem Lite v0.1.0 [M+H]+ 125.12633 predictedDeepCCS 1.0 (2019) [M+Na]+ 127.668012 predictedDarkChem Lite v0.1.0 [M+Na]+ 127.761412 predictedDarkChem Lite v0.1.0 [M+Na]+ 127.807512 predictedDarkChem Lite v0.1.0 [M+Na]+ 133.94817 predictedDeepCCS 1.0 (2019) [M+Na]+ 127.668012 predictedDarkChem Lite v0.1.0 [M+Na]+ 127.761412 predictedDarkChem Lite v0.1.0 [M+Na]+ 127.807512 predictedDarkChem Lite v0.1.0 [M+Na]+ 133.94817 predictedDeepCCS 1.0 (2019)
Targets
Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock newinsights and accelerate drug research.
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
- Kind
- Protein group
- Organism
- Not Available
- Pharmacological action
- Unknown
- Actions
- Substrate
- General Function
- Fad binding
- Specific Function
- Not Available
Components:
References
- Anderson RF, Patel KB, Stratford MR: Absorption spectra of radicals of substrates for p-hydroxybenzoate hydroxylase following electrophilic attack of the .OH radical in the 3 position. J Biol Chem. 1987 Dec 25;262(36):17475-9. [Article]
Drug created at June 13, 2005 13:24 / Updated at May 22, 2021 06:01